Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MD
Written by
Neurology Live
Published
0
comments
0
min
The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]